Amneal Pharmaceuticals (AMRX) Operating Leases (2018 - 2025)
Historic Operating Leases for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Q3 2025 value amounting to $26.4 million.
- Amneal Pharmaceuticals' Operating Leases rose 74.4% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.4 million, marking a year-over-year increase of 74.4%. This contributed to the annual value of $24.8 million for FY2024, which is 4927.01% down from last year.
- According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Operating Leases is $26.4 million, which was up 74.4% from $27.6 million recorded in Q2 2025.
- Amneal Pharmaceuticals' Operating Leases' 5-year high stood at $64.0 million during Q4 2021, with a 5-year trough of $22.9 million in Q1 2025.
- Over the past 5 years, Amneal Pharmaceuticals' median Operating Leases value was $28.3 million (recorded in 2023), while the average stood at $32.7 million.
- Per our database at Business Quant, Amneal Pharmaceuticals' Operating Leases surged by 683.31% in 2022 and then crashed by 4927.01% in 2024.
- Over the past 5 years, Amneal Pharmaceuticals' Operating Leases (Quarter) stood at $64.0 million in 2021, then fell by 7.45% to $59.2 million in 2022, then decreased by 17.42% to $48.9 million in 2023, then plummeted by 49.27% to $24.8 million in 2024, then increased by 6.41% to $26.4 million in 2025.
- Its Operating Leases was $26.4 million in Q3 2025, compared to $27.6 million in Q2 2025 and $22.9 million in Q1 2025.